STOCK TITAN

Latigo Biotherapeutics grants Singla 350K stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Latigo Biotherapeutics, Inc. (LTGO) Chief Medical Officer Neil Singla was granted 350,000 employee stock options on November 15, 2026, covering 350,000 shares of common stock. The options have an exercise price of $13.11 per share and expire November 14, 2036. The options vest in three installments through May 3, 2028: 25% on March 31, 2027, 25% on November 3, 2027, and 50% on May 3, 2028.

Insider Singla Neil
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F1 350,000 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 350,000 options (Direct)
Footnotes (1)
  1. F1. 25% of the total shares subject to this option shall vest on March 31, 2027, 25% of the total shares subject to this option shall vest on November 3, 2027, and 50% of the total shares subject to this option shall vest on May 3, 2028.
Options granted 350,000 options Granted to Neil Singla on November 15, 2026
Options held after grant 350,000 options Direct holdings reported following the grant
Exercise price $13.11 per share Price to exercise the options
First vesting installment 25% Scheduled to vest March 31, 2027
Second vesting installment 25% Scheduled to vest November 3, 2027
Final vesting installment 50% Scheduled to vest May 3, 2028
Option expiration November 14, 2036 Expiration date of the option award
Employee Stock Option (right to buy) technical
"the 350,000-option award to Neil Singla"
exercise price financial
"the options’ $13.11 per-share exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest technical
"25% of the options vest on March 31, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LTGO options did Neil Singla receive?

Neil Singla was granted 350,000 employee stock options on November 15, 2026, covering 350,000 shares of common stock.

When do Neil Singla’s LTGO options vest?

The options vest 25% on March 31, 2027, 25% on November 3, 2027, and 50% on May 3, 2028. The award has an exercise price of $13.11 per share and expires November 14, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Singla Neil

(Last)(First)(Middle)
C/O LATIGO BIOTHERAPEUTICS, INC.
1300 RANCHO CONEJO BLVD., SUITE 305

(Street)
THOUSAND OAKS CALIFORNIA 91320

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [ LTGO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$13.1111/15/2026A350,000 (1)11/14/2036Common Stock350,000$0350,000D
Explanation of Responses:
1. 25% of the total shares subject to this option shall vest on March 31, 2027, 25% of the total shares subject to this option shall vest on November 3, 2027, and 50% of the total shares subject to this option shall vest on May 3, 2028.
/s/ Sabrina Nieder, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading